Rectal Organoids Enable Personalized Treatment of Cystic Fibrosis
Gitte Berkers,
Peter van Mourik,
Annelotte M. Vonk,
Evelien Kruisselbrink,
Johanna F. Dekkers,
Karin M. de Winter-de Groot,
Hubertus G.M. Arets,
Rozemarijn E.P. Marck-van der Wilt,
Jasper S. Dijkema,
Maaike M. Vanderschuren,
Roderick H.J. Houwen,
Harry G.M. Heijerman,
Eduard A. van de Graaf,
Sjoerd G. Elias,
Christof J. Majoor,
Gerard H. Koppelman,
Jolt Roukema,
Marleen Bakker,
Hettie M. Janssens,
Renske van der Meer,
Robert G.J. Vries,
Hans C. Clevers,
Hugo R. de Jonge,
Jeffrey M. Beekman,
Cornelis K. van der Ent
Affiliations
Gitte Berkers
Department of Pediatric Pulmonology, Wilhelmina Children’s Hospital, University Medical Center Utrecht, Utrecht University, 3584 EA Utrecht, the Netherlands
Peter van Mourik
Department of Pediatric Pulmonology, Wilhelmina Children’s Hospital, University Medical Center Utrecht, Utrecht University, 3584 EA Utrecht, the Netherlands
Annelotte M. Vonk
Department of Pediatric Pulmonology, Wilhelmina Children’s Hospital, University Medical Center Utrecht, Utrecht University, 3584 EA Utrecht, the Netherlands; Regenerative Medicine Center Utrecht, University Medical Center Utrecht, Utrecht University, 3584 CT Utrecht, the Netherlands
Evelien Kruisselbrink
Department of Pediatric Pulmonology, Wilhelmina Children’s Hospital, University Medical Center Utrecht, Utrecht University, 3584 EA Utrecht, the Netherlands; Regenerative Medicine Center Utrecht, University Medical Center Utrecht, Utrecht University, 3584 CT Utrecht, the Netherlands
Johanna F. Dekkers
Hubrecht Institute for Developmental Biology and Stem Cell Research and University Medical Center Utrecht, 3584 CT Utrecht, the Netherlands
Karin M. de Winter-de Groot
Department of Pediatric Pulmonology, Wilhelmina Children’s Hospital, University Medical Center Utrecht, Utrecht University, 3584 EA Utrecht, the Netherlands
Hubertus G.M. Arets
Department of Pediatric Pulmonology, Wilhelmina Children’s Hospital, University Medical Center Utrecht, Utrecht University, 3584 EA Utrecht, the Netherlands
Rozemarijn E.P. Marck-van der Wilt
Department of Pediatric Pulmonology, Wilhelmina Children’s Hospital, University Medical Center Utrecht, Utrecht University, 3584 EA Utrecht, the Netherlands
Jasper S. Dijkema
Department of Pediatric Pulmonology, Wilhelmina Children’s Hospital, University Medical Center Utrecht, Utrecht University, 3584 EA Utrecht, the Netherlands
Maaike M. Vanderschuren
Department of Pediatric Pulmonology, Wilhelmina Children’s Hospital, University Medical Center Utrecht, Utrecht University, 3584 EA Utrecht, the Netherlands
Roderick H.J. Houwen
Department of Pediatric Gastroenterology, Wilhelmina Children’s Hospital, University Medical Center Utrecht, 3584 EA Utrecht, the Netherlands
Harry G.M. Heijerman
Department of Pulmonology, University Medical Center Utrecht, 3584 CX Utrecht, the Netherlands
Eduard A. van de Graaf
Department of Pulmonology, University Medical Center Utrecht, 3584 CX Utrecht, the Netherlands
Sjoerd G. Elias
Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, 3584 CX Utrecht, the Netherlands
Christof J. Majoor
Department of Respiratory Medicine, Amsterdam University Medical Centers, University of Amsterdam, 1105 AZ Amsterdam, the Netherlands
Gerard H. Koppelman
University of Groningen, University Medical Center Groningen, Beatrix Children’s Hospital, Department of Pediatric Pulmonology and Pediatric Allergology and GRIAC Research Institute, 9713 GZ Groningen, the Netherlands
Jolt Roukema
Department of Pediatric Pulmonology, Radboud University Medical Center, Amalia Children’s Hospital, 6525 GA Nijmegen, the Netherlands
Marleen Bakker
Department of Pulmonology, Erasmus MC, University Medical Center, 3015 GD Rotterdam, the Netherlands
Hettie M. Janssens
Department of Pediatrics, Division of Respiratory Medicine and Allergology, Erasmus MC-Sophia Children’s Hospital, University Medical Center, 3015 GD Rotterdam, the Netherlands
Renske van der Meer
Department of Pulmonology, Haga Teaching Hospital, 2545 AA The Hague, the Netherlands
Robert G.J. Vries
Hubrecht Organoid Technology (HUB), 3584 CM Utrecht, the Netherlands
Hans C. Clevers
Hubrecht Institute for Developmental Biology and Stem Cell Research and University Medical Center Utrecht, 3584 CT Utrecht, the Netherlands
Hugo R. de Jonge
Department of Gastroenterology and Hepatology, Erasmus University Medical Center, 3015 GD Rotterdam, the Netherlands
Jeffrey M. Beekman
Department of Pediatric Pulmonology, Wilhelmina Children’s Hospital, University Medical Center Utrecht, Utrecht University, 3584 EA Utrecht, the Netherlands; Regenerative Medicine Center Utrecht, University Medical Center Utrecht, Utrecht University, 3584 CT Utrecht, the Netherlands; Corresponding author
Cornelis K. van der Ent
Department of Pediatric Pulmonology, Wilhelmina Children’s Hospital, University Medical Center Utrecht, Utrecht University, 3584 EA Utrecht, the Netherlands; Corresponding author
Summary: In vitro drug tests using patient-derived stem cell cultures offer opportunities to individually select efficacious treatments. Here, we provide a study that demonstrates that in vitro drug responses in rectal organoids from individual patients with cystic fibrosis (CF) correlate with changes in two in vivo therapeutic endpoints. We measured individual in vitro efficaciousness using a functional assay in rectum-derived organoids based on forskolin-induced swelling and studied the correlation with in vivo effects. The in vitro organoid responses correlated with both change in pulmonary response and change in sweat chloride concentration. Receiver operating characteristic curves indicated good-to-excellent accuracy of the organoid-based test for defining clinical responses. This study indicates that an in vitro assay using stem cell cultures can prospectively select efficacious treatments for patients and suggests that biobanked stem cell resources can be used to tailor individual treatments in a cost-effective and patient-friendly manner. : Berkers et al. demonstrate that stem cell cultures (organoids) can be a tool for personalized medicine. They show a high correlation between in vitro and in vivo effects of drugs and demonstrate good-to-excellent predictive values of the organoid test for preclinical identification of responders to CFTR modulators. Keywords: organoids, personalized treatment, predicting, drug response, stem cell cultures, cystic fibrosis, CFTR